Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

Company Overview

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials. In parallel, Acrivon is advancing additional stapled-peptide programs directed at other oncogenic KRAS mutants such as G12D, with the goal of expanding its pipeline to address multiple unmet needs in solid tumor oncology.

Acrivon was established in 2021 as a spin-out from Calibr, the drug discovery division of The Scripps Research Institute, and is headquartered in Redwood City, California. The company leverages its origin in academic research to maintain close collaborations with leading cancer centers and translational science groups across North America and Europe.

Supported by a management team with extensive experience in biotechnology and pharmaceutical drug development, Acrivon is building strategic partnerships and advancing its peptide platform to potentially deliver first-in-class or best-in-class therapies for patients with RAS-mutant cancers. The company continues to focus on rigorous clinical development and regulatory engagement to bring novel peptide-based oncology treatments to market.

Key Stats

• Today's Range: $1.63 to $1.69
• 50-Day Range: $1.23 to $1.79
• 52-Week Range: $1.05 to $8.74
• Volume: 423,637 shs
• Average Volume: 3.47 million shs
• Market Capitalization: $51.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Acrivon Therapeutics Stock Analysis - MarketRank™

Acrivon Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 385th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Acrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Acrivon Therapeutics has a consensus price target of $15.00, representing about 820.2% upside from its current price of $1.63.

Amount of Analyst Coverage

Acrivon Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acrivon Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acrivon Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acrivon Therapeutics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.52% of the float of Acrivon Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Acrivon Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Acrivon Therapeutics has recently decreased by 20.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acrivon Therapeutics does not currently pay a dividend.

Dividend Growth

Acrivon Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.52% of the float of Acrivon Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Acrivon Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Acrivon Therapeutics has recently decreased by 20.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

12 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

13 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 333% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.90% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACRV Stock Analysis - Frequently Asked Questions

How have ACRV shares performed this year?

Acrivon Therapeutics' stock was trading at $6.02 at the beginning of the year. Since then, ACRV shares have decreased by 72.9% and is now trading at $1.63.

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) issued its earnings results on Wednesday, August, 13th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.02.

When did Acrivon Therapeutics IPO?

Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

Who are Acrivon Therapeutics' major shareholders?

Top institutional shareholders of Acrivon Therapeutics include Jane Street Group LLC (0.99%), Marshall Wace LLP (0.58%), Geode Capital Management LLC (0.52%) and XTX Topco Ltd (0.34%). Insiders that own company stock include Ra Capital Management, LP, Ltd Chione and Perceptive Advisors Llc.
View institutional ownership trends.

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acrivon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/20/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACRV
• CIK: 1781174
• Web: www.acrivon.com
• Phone: 617-207-8979
• Fax: N/A
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acrivon Therapeutics: $15.00
• High Price Target: $27.00
• Low Price Target: $6.00
• Potential Upside/Downside: +820.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.78%
• Return on Assets: -46.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.31
• Quick Ratio: 10.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.68 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 31,460,000
• Free Float: 27,713,000
• Market Cap: $51.28 million
• Optionable: Not Optionable
• Beta: 1.66